NCT06839339尚未招募2 期
A Phase II, Randomized, Positive-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Single Suprachoroidal Space Injection of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Macular Degeneration (wAMD)
Beijing Anlong Biopharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年2月18日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Evaluate the effect of AL-001 on BCVA
研究概览
简要总结
This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will be randomized in Cohorts 1 and 2 to receive AL-001 administered via suprachoroidal space injection, Cohort 3 to receive Aflibercept.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age≥ 50 and ≤
- •The study eye was diagnosed with subfoveal active choroidal neovascularization (CNV) lesions secondary to wAMD.
- •The study eye has response to anti-VEGF injections.
- •The subject or their legal representative agrees to participate in this study and signs a written ICF.
排除标准
- •Non-wAMD induced CNV or macular edema in the study eye.
- •Non-wAMD induced eye conditions that may affect central vision or medical history that may seriously affect central vision in the study eye.
- •Uncontrolled glaucoma in the study eye.
- •History of vitreoretinal surgery, antiglaucoma trabeculectomy, or other anti-glaucoma filtering surgery in the study eye.
- •Refractive interstitial opacity that significantly affects visual function assessment or fundus examination in the study eye.
- •Ametropia (high myopia or high hyperopia) > 8.0D in the study eye, or significant posterior scleral staphyloma in the study eye.
- •Malignant tumor in any eye, including but not limited to eye lymphoma or choroidal melanoma.
- •None of intraocular inflammation in the study eye.
- •Other conditions that may affect compliance or may not be suitable to participate in this trial in the opinion of investigator.
研究组 & 干预措施
AL-001 Dose 1
Experimental
Injection of dose 1
干预措施: AL-001 (Drug)
AL-001 Dose 2
Experimental
Injection of dose 2
干预措施: AL-001 (Drug)
Aflibercept
Active Comparator
Intravitreal injection
干预措施: Aflibercept (Drug)
结局指标
主要结局
Evaluate the effect of AL-001 on BCVA
时间窗: Week 24
Change in BCVA
次要结局
- Safety(Week 56)
- Evaluate the effect of AL-001 on central retinal thickness (CRT)(Week 56)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye DiseaseDry Eye DiseaseNCT05238597Aramis Biosciences, Inc.207
已完成
2 期
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt DiseaseStargardt DiseaseNCT05417126Nanoscope Therapeutics Inc.6
已完成
1 期
Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionPrimary Open-angle GlaucomaOcular HypertensionNCT01528111Lexicon Pharmaceuticals63
已完成
2 期
RMP-A03 Ocular Suspension in Patients With PterygiumPterygiumNCT05794204Suzhou Raymon Pharmaceuticals Company, Ltd.77
已完成
2 期
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]Retinitis PigmentosaRetinal DiseasesEye DiseasesEye Diseases, HereditaryRetinal DystrophiesRetinal DegenerationRetinitisNCT04945772Nanoscope Therapeutics Inc.27